68Ga NTA 14
Alternative Names: 68Ga-NTA-14Latest Information Update: 20 Sep 2023
At a glance
- Originator
- Developer Clovis Oncology
- Class Imaging agents; Peptidomimetics; Radioisotopes; Radiopharmaceutical diagnostics
- Mechanism of Action Emission-computed tomography enhancers; Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 10 Jul 2023 Discontinued - Clinical-Phase-Unknown for Prostate cancer (Diagnosis, Hormone refractory, Metastatic disease) in Australia (IV) due to wind-down and the liquidation of the company
- 13 Dec 2021 Clinical trials in Prostate cancer (Metastatic disease, Treatment-resistant) in USA (IV) (ACTRN12621001704886)